3 weeks Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet Zacks
The average of price targets set by Wall Street analysts indicates a potential upside of 58.3% in CRISPR Therapeutics (CRSP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
X